Dr. Fred R. Hirsch is Executive Director at the Center for Thoracic Oncology in The Tisch Cancer Institute at Mount Sinai (TCI) and Professor of Medicine and Pathology as well as the Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. He is also Associate Director of Biomarker Discovery for TCI.

Before joining Mount Sinai, he was a professor of Medicine and Pathology at the University of Colorado for 18 years and Chief Executive Officer of the International Association for the Study of Lung Cancer (IASLC) for five years. Dr. Hirsch’s career in lung cancer research spans more than 25 years and includes translational research, targeted therapies and early detection of lung cancer. His research has helped identify and validate prognostic markers for lung cancer outcomes and biomarkers for personalized lung cancer therapies that illustrate how these therapies work and who is most likely to benefit from them. Dr. Hirsch has led many large collaborative NIH grants, and he is currently the PI for a large NIH- grant studying COVID 19 infection/-vaccination and lung cancer.

Dr. Hirsch has received a number of awards and honors, including the IASLC Mary Matthews Award for Translational Research in Lung Cancer in 2007; the Japanese Lung Cancer Society Merit Award in 2010; the Addario Foundation Lecture Award in 2015; and the Waun Ki Hong Lectureship Award in 2019. The CURE Media Group / MJH Life Sciences honored Dr. Hirsch as the inaugural “Lung Cancer Hero 2020”, and most recently ESMO; Heine Hansen Life Time Achievement Award 2022. Dr. Hirsch received both his doctor of medicine and PhD degrees from the University of Copenhagen. He has contributed to more than 470 publications in peer-reviewed journals.